Komori
Alfresa Holdings (2784) · FactFirst stated

Revenue and profit growth in the pharmaceuticals and related products manufacturing business in Q3 of FY2017

First written in FY2017-Q3. . Latest entry: FY2017-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Higher revenue and profit in the pharmaceuticals and related products manufacturing businessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2017-Q3First statedAnnual report

    「当第３四半期連結累計期間の業績は、売上高299億71百万円（前年同期比33.6％増）、営業利益15億1百万円（同46.5％増）となりました。」

    サンノーバの事業承継や中国の新工場棟竣工を含む医薬品等製造事業は増収増益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.